SSKN

STRATA is a sub-scale dermatology-device maker whose own 10-K states its 'history of operating losses and current default on our long-term debt raise substantial doubt regarding our ability to continue as a going concern.' That single disclosure dominates everything else: this is not a valuation question, it is a solvency question. The company carries $15.3M of debt classified as a current portion (long-term debt now $0, having been reclassified after the default) against just $7.91M of cash. It cannot repay from the balance sheet, and operating cash flow swung to -$2.79M — so it is burning cash, not generating it, while the maturity is already past due. Stockholders' equity has collapsed 68% to $2.98M against $30.1M of liabilities (10.09x leverage), and retained earnings sit at -$250M — a company that has destroyed a quarter-billion dollars of capital over its life.

The operating business is also shrinking, not stabilizing. Revenue fell 8.5% to $30.7M and is now below its FY2021 level ($30.0M), meaning zero five-year growth despite the losses. The installed base is contracting — XTRAC systems in U.S. dermatology offices fell to 842 from 864 — which directly pressures the per-procedure recurring-revenue model the company depends on. Gross margin is a respectable 58.3%, but that never converts to profit: operating margin is -15.3% and the company has lost money every single year from FY2021 to FY2025. R&D was slashed 52% to just $421K, a sign of a company cutting future product investment to conserve cash rather than one investing to grow. Management also flags fresh macro risks — 2025 U.S. import tariffs hitting its Dermatology Procedures Equipment segment, rare-gas supply disruption from the Russia-Ukraine war for its lasers, and early-2026 Middle East conflict.